278 related articles for article (PubMed ID: 35384496)
61. Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial.
Lueong SS; Herbst A; Liffers ST; Bielefeld N; Horn PA; Tannapfel A; Reinacher-Schick A; Hinke A; Hegewisch-Becker S; Kolligs FT; Siveke JT
Clin Chem; 2020 Dec; 66(12):1510-1520. PubMed ID: 33257977
[TBL] [Abstract][Full Text] [Related]
62. Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies.
Fu Y; Yang Z; Hu Z; Yang Z; Pan Y; Chen J; Wang J; Hu D; Zhou Z; Xu L; Chen M; Zhang Y
Hepatol Int; 2022 Aug; 16(4):868-878. PubMed ID: 35674872
[TBL] [Abstract][Full Text] [Related]
63. Treatment stratification and prognosis assessment using circulating tumor DNA in locally advanced rectal cancer: A systematic review and meta-analysis.
Mi J; Wang R; Han X; Ma R; Zhao D
Cancer Med; 2023 Sep; 12(17):17934-17944. PubMed ID: 37553845
[TBL] [Abstract][Full Text] [Related]
64. Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases.
Bolhuis K; van 't Erve I; Mijnals C; Delis-Van Diemen PM; Huiskens J; Komurcu A; Lopez-Yurda M; van den Broek D; Swijnenburg RJ; Meijer GA; Punt CJA; Fijneman RJA
EBioMedicine; 2021 Aug; 70():103498. PubMed ID: 34333237
[TBL] [Abstract][Full Text] [Related]
65. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer.
Kotani D; Oki E; Nakamura Y; Yukami H; Mishima S; Bando H; Shirasu H; Yamazaki K; Watanabe J; Kotaka M; Hirata K; Akazawa N; Kataoka K; Sharma S; Aushev VN; Aleshin A; Misumi T; Taniguchi H; Takemasa I; Kato T; Mori M; Yoshino T
Nat Med; 2023 Jan; 29(1):127-134. PubMed ID: 36646802
[TBL] [Abstract][Full Text] [Related]
66. Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling.
Yaegashi M; Iwaya T; Sasaki N; Fujita M; Ju Z; Siwak D; Hachiya T; Sato K; Endo F; Kimura T; Otsuka K; Sugimoto R; Sugai T; Liotta L; Lu Y; Mills GB; Nakagawa H; Nishizuka SS
Br J Cancer; 2021 Apr; 124(9):1556-1565. PubMed ID: 33658639
[TBL] [Abstract][Full Text] [Related]
67. Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer.
Fakih M; Sandhu J; Wang C; Kim J; Chen YJ; Lai L; Melstrom K; Kaiser A
JAMA Netw Open; 2022 Mar; 5(3):e221093. PubMed ID: 35258578
[TBL] [Abstract][Full Text] [Related]
68. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
69. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer.
Luo H; Zhao Q; Wei W; Zheng L; Yi S; Li G; Wang W; Sheng H; Pu H; Mo H; Zuo Z; Liu Z; Li C; Xie C; Zeng Z; Li W; Hao X; Liu Y; Cao S; Liu W; Gibson S; Zhang K; Xu G; Xu RH
Sci Transl Med; 2020 Jan; 12(524):. PubMed ID: 31894106
[TBL] [Abstract][Full Text] [Related]
70. The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis.
Faulkner LG; Howells LM; Pepper C; Shaw JA; Thomas AL
Br J Cancer; 2023 Jan; 128(2):297-309. PubMed ID: 36347967
[TBL] [Abstract][Full Text] [Related]
71. Clinical significance of circulating tumor DNA in localized non-small cell lung cancer: a systematic review and meta-analysis.
Guo RQ; Peng JZ; Sun J; Li YM
Clin Exp Med; 2023 Sep; 23(5):1621-1631. PubMed ID: 36315311
[TBL] [Abstract][Full Text] [Related]
72. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
[TBL] [Abstract][Full Text] [Related]
73. Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction.
Nassar FJ; Msheik ZS; Nasr RR; Temraz SN
Clin Epigenetics; 2021 May; 13(1):111. PubMed ID: 34001239
[TBL] [Abstract][Full Text] [Related]
74. Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis.
Wang B; Pei J; Wang S; Cheng K; Yu J; Liu J
Crit Rev Oncol Hematol; 2022 Sep; 177():103771. PubMed ID: 35905822
[TBL] [Abstract][Full Text] [Related]
75. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer.
Zhou H; Zhu L; Song J; Wang G; Li P; Li W; Luo P; Sun X; Wu J; Liu Y; Zhu S; Zhang Y
Mol Cancer; 2022 Mar; 21(1):86. PubMed ID: 35337361
[TBL] [Abstract][Full Text] [Related]
76. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
Papakonstantinou A; Gonzalez NS; Pimentel I; Suñol A; Zamora E; Ortiz C; Espinosa-Bravo M; Peg V; Vivancos A; Saura C; Villacampa G; Oliveira M
Cancer Treat Rev; 2022 Mar; 104():102362. PubMed ID: 35219090
[TBL] [Abstract][Full Text] [Related]
77. Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen: Comparison of Surveillance Strategies Among Patients Who Underwent Resection of Colorectal Cancer-A Systematic Review and Meta-analysis.
Dawood ZS; Alaimo L; Lima HA; Moazzam Z; Shaikh C; Ahmed AS; Munir MM; Endo Y; Pawlik TM
Ann Surg Oncol; 2023 Jan; 30(1):259-274. PubMed ID: 36219278
[TBL] [Abstract][Full Text] [Related]
78. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
79. Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer.
Emiloju OE; Storandt M; Zemla T; Tran N; Jethwa K; Mahipal A; Mitchell J; Thiels C; Mathis K; McWilliams R; Hubbard J; Sinicrope F; Shi Q; Jin Z
JCO Precis Oncol; 2024 Jan; 8():e2300127. PubMed ID: 38237099
[TBL] [Abstract][Full Text] [Related]
80. A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer.
Guven DC; Sahin TK; Yildirim HC; Aktepe OH; Dizdar O; Yalcin S
Crit Rev Oncol Hematol; 2021 Dec; 168():103528. PubMed ID: 34800650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
